WCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
|Pioneer Investments 242,800 sh (New)|
Mario Gabelli 16,500 sh (New)
Jim Simons 2,893,400 sh (+201.90%)
Diamond Hill Capital 1,418,393 sh (+50.40%)
Private Capital 1,550,780 sh (+1.75%)
|Louis Moore Bacon 300,000 sh (unchged)||Stanley Druckenmiller Sold Out|
Louis Moore Bacon Sold Out
Joel Greenblatt 1,224,629 sh (-10.39%)
RS Investment Management 5,331,335 sh (-30.29%)
Paul Tudor Jones 12,900 sh (-48.40%)
Steven Cohen 438,812 sh (-90.32%)
|Jeremy Grantham 103,693 sh (New)|
Jim Simons 4,617,505 sh (+59.59%)
Private Capital 1,572,147 sh (+1.38%)
|Pioneer Investments 242,800 sh (unchged)||Paul Tudor Jones Sold Out|
Mario Gabelli Sold Out
RS Investment Management 5,302,224 sh (-0.55%)
Steven Cohen 431,112 sh (-1.75%)
Joel Greenblatt 1,026,192 sh (-16.20%)
Diamond Hill Capital 704,340 sh (-50.34%)
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
|Industry:||Drug Manufacturers » Drug Manufacturers - Specialty & Generic|
|Compare:||TKPYY, TEVA, AGN, FRX, MRX » details|
|Traded in other countries:||G3LA.Germany,|
|Warner Chilcott Limited was formed through a series of acquisitions and divestitures. It began commercial operations on January 5, 2005 when it acquired Warner Chilcott PLC ("Predecessor"). Its Predecessor was incorporated in 1968 as a sales and marketing organization focused on branded pharmaceutical products in Northern Ireland, but in September 2000 expanded into the U.S. pharmaceuticals market through the acquisition of a U.S. pharmaceutical business that marketed a portfolio of products including OVCON and ESTRACE Cream. It is a global pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacture and promotion of its products. It markets and sells the following principal products: Gastroenterology, Women's Healthcare, Dermatology and Urology. The Company markets its products mainly to physicians and employs marketing techniques to identify and target physicians with the highest potential to prescribe its products. Its branded products compete with brands marketed by other pharmaceutical companies including large, fully integrated concerns with financial, marketing, legal and product development resources greater than theirs. The U.S. pharmaceutical industry is subject to regulation by national, regional, state and local agencies.|
|My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013|
|4 Top-Performing Healthcare Dividend Stocks with Single-Digit P/Es Jul 02 2013|
|'Magic Formula' Inventor Joel Greenblatt New Buys Rundown May 24 2013|
|My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013|
|comment on WCRX Apr 21 2013|
|Weekly Guru Bargains Highlights: WCRX, IOC, QCOR, PWE, PGH Dec 30 2012|
|Weekly Guru Bargains Highlights: BIG, RATE, WCRX, BPT, MCP Dec 24 2012|
|4 International Stocks at 52-Week Lows – December 2012 Edition Dec 14 2012|
|many gurus, turn aro Oct 15 2012|
|Weekly Guru Bargains Highlights: WCRX, NIHD, EBR, CAJ, CIG Oct 06 2012|